ArticleArchives of microbiology2021
Targeting Staphylococcus aureus and its biofilms with novel antibacterial compounds produced by Lactiplantibacillus plantarum SJ33.
Article in Archives of microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- Potential of Fermented Food-DerivedInternational journal of molecular sciences · 2026Article
- Topical Probiotics as a Novel Approach in the Treatment of Chronic Dermatoses Associated with Skin Dysbiosis: A Narrative Review.International journal of molecular sciences · 2025Review
- DisarmingPathogens (Basel, Switzerland) · 2025Review
- Update of the list of qualified presumption of safety (QPS) recommended microbiological agents intentionally added to food or feed as notified to EFSA 17: suitability of taxonomic units notified to EFSA until September 2022.EFSA journal. European Food Safety Authority · 2023Article
- Antimicrobial and anti-biofilm activity of Polygonum chinense L.aqueous extract against Staphylococcus aureus.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of microbial resistance to conventional antibiotics, partially attributed to biofilm formation, has urged for new antimicrobial compounds. Here, we reported two novel low molecular weight (LMW) compounds from Lactiplantibacillus plantarum SJ33 and evaluated their biofilm inhibitory effects on Staphylococcus aureus. The compounds C1 and C2 were purified by RP-HPLC and structurally identified as 3-amino-5-hydroxy-6-(hydroxymethyl)-4-(1-hydroxyprop-2-yn-1-yl)-3,3a,4,5,6,7a-hexahydro-7H-indazol-7-one and 1-(dimethylamino)-3-hydroxy-3-((2-hydroxypropan-2-yl)oxy)-1-(methylamino)-butan-2-one by spectroscopic techniques. High ESI-MS data confirmed the molecular weight of C1 and C2 as 254.1141 and 234.1658 Da, respectively. Time-kill assay demonstrated bactericidal action of compounds, whereas scanning electron microscopy revealed morphological changes in treated S. aureus MTCC96 and methicillin-resistant S. aureus (MRSA) cells. The antibacterial compounds reduced biofilm formation in S. aureus MTCC96 and MRSA by crystal violet assay. Further, fluorescence and scanning electron microscopic images exhibited biofilm formation by pathogens and biofilm inhibition by compounds treatment. The Quantitative RT PCR revealed the down-regulation of icaC and icaD genes involved in intercellular adhesion of biofilms. The results confirmed the anti-biofilm activity of novel LMW compounds by eliminating preformed biofilms formed by S. aureus MTCC96 and MRSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.